Table 2.
Clinical characteristics.
| Group A (n=76) | Group B (n=71) | Group C (n=102) | |
|---|---|---|---|
| Men | 26 (34.2) | 16 (22.5%) | 31 (30.6%) |
| Women | 50 (65.8%) | 55 (77.5%) | 71 (69.4%) |
| Age (years)# | 40.33±13.7 | 49.14±13.97 | 41.62±14.55 |
| CEA (ng/mL)# | 1.99±1.61 | 2.44±1.82 | 1.58±1.07 |
| CREA (µmol/L) | 73.28±18.94 | 68.49±19.58 | 68.85±17.15 |
| CK (U/L)* | 71.28±48.93 | 92.38±59.93 | 93.18±78.44 |
| CK-MB (U/L) | 12.95±13.31 | 11.52±5.12 | 11.37±9.68 |
| UA (µmol/L)* | 442.84±166.1 | 362.71±113.43 | 388.74±96.89 |
| ALT (U/L)* | 23.33±26.86 | 21.23±15.82 | 18.05±15.9 |
| AST (U/L)* | 25.64±10.42 | 27.75±15.41 | 21.48±6.6 |
| HGB (g/L)* | 145.82±30.12 | 135.9±30.31 | 132.85±17.26 |
| WBC count (×109/L)* | 7.22±2.17 | 6.35±1.52 | 6.31±1.44 |
| BNP (pg/mL)* | 1355.66±1651.82 | 704.89±999.03 | 238.83±504.62 |
| TNT (ng/mL)# | 11.12±9.66 | 51.93±249.56 | 5.32±3.94 |
| sPAP (mmHg)# | 96.21±31.59 | 49.68±11.06 | 31.72±8.16 |
| dPAP (mmHg)# | 36.67±16.24 | 17.08±5.57 | 9.11±3.75 |
| mPAP (mmHg)# | 58.66±20.21 | 30.2±4.83 | 17.31±4.51 |
| PVR (Wood units)# | 10.12±7.01 | 2.19±0.56 | 2.2±1.1 |
| PO (L/minute)# | 7.24±3.07 | 15.79±5.49 | 10.18±4.72 |
| PI (L/(minutes×m2))# | 4.82±2.15 | 10.68±4.66 | 6.54±3.19 |
| Qp/Qs# | 1.61±0.96 | 3.22±1.5 | 1.9±0.87 |
Values are n (%) or mean ± standard deviation.
*P<0.05, #P<0.01.
CEA, carcinoembryonic antigen; CREA, creatinine, CK, creatine kinase; UA, uric acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HGB, hemoglobin; WBC, white blood cell; BNP, N-terminal pro-brain natriuretic peptide; TNT, troponin T; sPAP, systolic pulmonary arterial pressure; dPAP, diastolic pulmonary arterial pressure; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; PO, pulmonary output; PI, pulmonary index; Qp/Qs, ratio of blood flow quantity between the pulmonary and systemic circulations.